Search results for " monoclonal" in Articles / App Notes
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
This early screening approach has identified cryptic aberrant splice sites in multiple therapeutic candidates including monoclonal antibodies, bispecific antibodies, and fusion proteins, therefore pre…
Article
Host-Cell Protein Measurement and Control
In a typical recovery process for a therapeutic monoclonal antibody, the highest concentration of HCP is detected in the harvested cell culture fluid (HCCF), and then cleared through additional downst…
Article
The Bullish Outlook for Biosimilars
In 2013, the EU’s decision to formally approve both Remsima (infliximab) and Inflectra (infliximab)--the world’s first monoclonal antibody (mAb) biosimilars by Celltrion and Hospira, respectively--rep…
Article
What Drove Biopharma Development in 2014?
To that end, PDF articles and posters related to monoclonal antibodies (mAb) were well received by website visitors. In fact, the monoclonal antibody market represents the fastest growing segment with…
Article
Address the complexity of protein characterization
Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant clinical success and have been used to provide effective treatment for a range of diseases. Durin…
Article
Top Tips for Successful Development of Antibody Chromatography Processes
I'm joined today by Jakob Liderfelt, a Global Product Manager for monoclonal antibody polishing with Cytiva. Jakob, thank you so much for your time today.
Jakob Liderfelt: It's very nice …
Article
Selecting Chromatography Resins for Bispecific Antibody Purification
Their purification can be more challenging than traditional monoclonal antibodies (mAbs), however, due to the increased level of product-related impurities with high similarity to the desired bsAbs. A…
Article
Top challenges in recombinant protein purification process development
First of all, why can process development be much more complex for recombinant proteins compared to traditional monoclonal antibodies?
Emma Lind: Yes. Well, for recombinant proteins, you often don…
Article
Pulling Out All the Stops in mAb Manufacturing
While the biopharma industry is pushing the barriers with antibody development, it must also contend with contemporary challenges in bulk monoclonal antibody (mAb) manufacturing. The need for…
Article
Pushing the Barriers in Next-Gen Antibody Development
Continued development of new and next-generation antibodies is spurred by the increasing demand for more effective and custom-tailored biologic therapies. In particular, bispecific antibodi…